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S U M M A R Y
This paper reviews the epidemiological data describing meningococcal disease in the Middle East and
North Africa (MENA). While meningococcal disease remains an important cause of endemic and
epidemic disease in many MENA countries, existing published epidemiological data appear limited,
fragmented, and collected via disparate methodologies. Children aged 5 years and younger are
predominantly affected, though outbreaks of the disease often affect older age groups. Whilst serogroup
A remains a main cause of meningococcal disease in the region, cases of serogroup B, W-135, and Y have
been increasingly reported over the last two decades in some countries. The Hajj pilgrimage is a key
factor inﬂuencing outbreaks and transmission, and the use of vaccines has minimized the effects on the
home countries of the pilgrims and has decreased global dissemination of disease. Wider use of available
polyvalent meningococcal conjugate vaccines may provide broader protection against the range of
serogroups causing disease or posing a threat in the region. In addition, strengthening regional
surveillance systems and regularly publishing reports with reliable estimates of disease incidence,
carriage, disease-related mortality, and sequelae may facilitate the development of appropriate
interventions and public health strategies regarding meningococcal disease within the region.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Neisseria meningitidis is consistently reported to be one of the
leading causes of bacterial meningitis in the Middle East and North
Africa (MENA) region.1–5 This region has no precise deﬁnition or
distinct boundary, but is generally considered to range from
Turkey in the north to Sudan in the south, and from Morocco in the
west to Pakistan in the east (Figure 1). The epidemiology of
meningococcal disease in MENA is affected by the proximity of the
region to the African meningitis belt, which extends from Senegal
in the west to Ethiopia in the east. In this region, meningococcal
disease incidence rates are several times higher than those seen in
industrialized countries, sometimes exceeding 1000 cases per
100 000 population during regular N. meningitidis serogroup A
outbreaks.6 Whilst serogroup A predominates in the meningitis
belt, serogroup W-135 has also been an important cause of more§ Data were presented at the 27th Annual Meeting of the European Society for
Paediatric Infectious Diseases (ESPID), Brussels, Belgium, June 9–13, 2009.
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http://dx.doi.org/10.1016/j.ijid.2012.03.011recent disease outbreaks, with serogroup C responsible for smaller
more historical outbreaks and recent evidence that serogroup X may
now be emerging.6,7 The meningitis belt is also particularly relevant,
as large numbers of Muslim pilgrims participate in the annual Hajj
pilgrimage to Saudi Arabia. Sudan, in particular, has a high burden of
disease, and has experienced several large outbreaks, leading to
mass vaccination campaigns over the past couple of decades.8–10
MENA also borders Europe and Asia. While Asia is historically
characterized by serogroup A and C, serogroups B and C account for
the majority of disease in Europe, as in the Americas, with serogroup
Y also contributing substantially to the burden of meningococcal
disease in the USA.11,12 The variation in common serogroups in the
bordering regions, and particularly in the home countries of Hajj
pilgrims,13 has implications for the epidemiology of N. meningitidis
and public health interventions in MENA.
The dry season in some MENA countries and parts of the
meningitis belt is characterized by dust winds and cold nights.
These conditions, combined with upper respiratory tract infections
that damage the nasopharyngeal tract, are thought to lead to an
increased risk of meningococcal disease.14 There is substantial
variability in socioeconomic conditions across MENA, from low-
income countries such as Afghanistan to high-income countriesses. Published by Elsevier Ltd. All rights reserved.
Figure 1. The MENA region (dark gray) highlighting the area associated with Hajj and Umra pilgrimages.
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variation within the region is also reﬂected in the extremes in
health care systems by country, as well as in varying public health
resources and priorities across the region. These factors are likely
to contribute to variations in the incidence of meningococcal
disease and other diseases across the region.
Annual Hajj pilgrimages and smaller Umra pilgrimages have
historically played a key role in the regional (and to some extent
global) spread of meningococcal disease, and have inﬂuenced
vaccination policies in the region. The mass travel and overcrowded
conditions associated with these pilgrimages can facilitate the rapid
spread of N. meningitidis amongst pilgrims and Saudi nationals.
Several important outbreaks in association with the Hajj have
affected Saudi residents and pilgrims, with pilgrimage sites being
most affected. There have been multiple serogroup A outbreaks,15–17
as well as an outbreak in 2000 which was shown to be a result of two
concurrent outbreaks, one caused by serogroup A and one caused by
serogroup W-135.16 In addition to localized Hajj outbreaks, the
resulting meningococcal carriage can also result in further
dissemination in the pilgrims’ home countries, creating potential
for future outbreaks internationally.13,18,19
A better understanding of the causes and widespread con-
sequences of the frequent outbreaks, strain-speciﬁc epidemiology,
and vaccination strategies across MENA are thus important to
assess the best way to reduce the impact of meningococcal disease
in the future, not only for MENA, but also for surrounding regions
and other parts of the world. Unfortunately, the vast size of the
region, armed conﬂict within the region, varying economic
conditions, and other public health priorities have affected data
collection and data availability regarding the burden of meningo-
coccal disease, resulting in a limited description of the meningo-
coccal disease burden in the region in the published literature. We
reviewed the available historical and contemporary epidemiology
of meningococcal disease for countries in this region, including
serogroup distribution, surveillance, and factors inﬂuencing
disease occurrence, carriage, and transmission, as well as key
issues for vaccine selection and immunization policies in MENA.
Due to the proximity and importance of meningococcal disease in
Sudan, data from Sudan were also included when relevant.2. Methods
A number of different sources were used for this review in order
to incorporate international and regional epidemiological data.
Several literature databases were searched, including PubMed,
Medline, Cochrane Library, and Index Medicus for the Eastern
Mediterranean Region, and international and government health
care websites, using the search terms listed below. In addition,
output from the MENA Vaccine Preventable Disease Advisory
Board meeting that took place in Cairo in June of 2007 was
reviewed for relevant data. The 23 countries included in the review
are: Afghanistan, Algeria, Bahrain, Egypt, Iran, Iraq, Israel, Jordan,
Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan, Palestine, Qatar,
Saudi Arabia, Sudan, Syria, Tunisia, Turkey, the UAE, and Yemen.
The worldwide impact of meningococcal disease associated with
the Hajj and Umra pilgrimages was also appraised. This review was
focused on the published data from the period 1986 through 2011.
The search terms were reﬁned after the initial search. Initial
search terms were: [Neisseria meningitidis], [Meningococcal
disease], [Meningococcaemia or Meningococcemia], [Meningococ-
cus], [Meningitis], [Pneumonia], [Septicaemia or Septicemia].
3. Meningococcal disease surveillance networks in the region
and availability of routine data in MENA countries
Although surveillance systems for meningococcal disease exist
in a number of countries in MENA, resulting data are not routinely
made publicly available, and publications based on the data are
sporadic and scarce. The World Health Organization (WHO)
recommends surveillance of meningococcal disease through
routine data collection for cases of disease at each health facility
level, routine reporting of collected information to a central
location, and regular review of this information to translate the
reporting into early control measures. Routine collection of data on
endemic disease is vital in order to differentiate patterns of cases
that indicate the emergence of an epidemic, and to guide public
health guidelines and interventions, which require accurate
information on the burden of disease.14 Surveillance systems for
bacterial meningitis and/or meningococcal disease are in place in
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and Saudi Arabia. In addition to the countries with established
surveillance systems, available sources report that meningitis is a
notiﬁable disease in Afghanistan,20 Kuwait,3 Morocco,8 and the
UAE.21 Turkey has a hospital-based surveillance and reporting
network, as well as laboratory support, though at times the
program has lacked regular support.22 In Saudi Arabia, the
Preventive Medicine Department at the Ministry of Health
(MoH), Riyadh, operates a surveillance system as part of the
Meningococcal Meningitis Control Program. This includes imme-
diate reporting by all health facilities of any suspected meningitis
cases to one of 20 health directorates, who then implement
preventative measures and follow the cases through to ﬁnal
diagnosis.17 While Saudi Arabia has a good routine surveillance
capacity, the data from the program are not made publicly
available. In 1998 the Egyptian MoH, in collaboration with the US
Naval Medical Research Unit No. 3, established a network of 12
infectious disease hospitals in diverse areas of the country,
enhancing meningitis surveillance. Clinicians were trained to
use standardized case deﬁnitions as part of this effort, and a
reference laboratory was set up to monitor activities and provide
quality control.23 In Lebanon, a national sentinel surveillance
system network for bacterial meningitis was set up by the
Epidemiological Surveillance Unit of the MoH.24 A national
surveillance system was established in Oman in 1991, in which
meningococcal disease is classiﬁed as a group A disease; cases
should be reported to the MoH within 24 h of case detection. The
epidemic threshold is deﬁned as three or more conﬁrmed cases
from one village within 1 week. All meningococcal isolates are
serogrouped and tested for antibiotic sensitivity at the Central
Public Health Laboratory.24 In Kuwait the Department of Preven-
tive Medicine and Communicable Diseases of the MoH is notiﬁed of
all childhood cases of clinically suspected meningitis by the
treating doctor through their local ofﬁce in each hospital.3
4. Current and historical use of meningococcal vaccines in
MENA
Meningococcal vaccine policies for routine vaccination in
individual countries in MENA are limited. Vaccine policies have
largely been shaped by outbreaks in the region, especially those
among Hajj pilgrims and their close contacts. The WHO
International Coordinating Group on Vaccine Provision for
Meningitis Control was established after outbreaks in 1995–96
in Africa and works to ensure the availability and rational
distribution of emergency supplies of meningococcal vaccine to
countries experiencing epidemic meningococcal meningitis.25
Only Bahrain, Egypt, Syria, and Libya include meningococcal
vaccines in their Expanded Program on Immunization (EPI). These
countries use polysaccharide MenACW-135Y vaccines, with the
exception of Egypt, where the MoH initiated a school-based
vaccination program with a polysaccharide MenAC vaccine in
1992, following the serogroup A-associated outbreaks in 1988–
91.26 Although Saudi Arabia does not include a meningococcal
vaccine in its EPI, the country has regularly updated its vaccination
policies in an attempt to control the recurring outbreaks associated
with the Hajj, and requires proof of vaccination for all arrivals
attending the Hajj or Umra pilgrimage or arriving for seasonal
work, and all arrivals from countries of the African meningitis belt.
Vaccination is also required for interior pilgrims, all citizens and
residents of Medina and Mecca who have not been vaccinated in
the past 3 years, all citizens and residents going to Hajj, all Hajj
workers not vaccinated in the past 3 years, and any individual
working at entry points into Saudi Arabia.27–29 Targeted vaccina-
tion of high-risk groups, such as Hajj pilgrims and military
personnel, using polysaccharide MenACW-135Y vaccines is alsomandated by the governments in Bahrain, Egypt, Kuwait, Libya,
Oman, Qatar, Saudi Arabia, Syria, and Turkey.
Countries with some estimates for vaccine coverage with
meningococcal vaccines in use include Saudi Arabia, Bahrain, the
UAE, and Morocco. Approximately 150 000 individuals were
vaccinated annually nationwide in Morocco between 1998 and
2001.30 In 2000, 475 000 Saudi residents were vaccinated in Mecca,
162 000 in Medina, and 375 000 at ports of entry. A survey in
Riyadh in 2002 showed that only 51% of individuals were
vaccinated, and only 52% of those vaccinated had received the
vaccine within the previous 3 years.8 Targeted vaccination of Hajj
pilgrims and Mecca and Medina residents in Saudi Arabia has
improved vaccine coverage in Mecca from 1% in 1991–92 to 70–
73% in 1992–93. However, overall it appears that vaccine coverage
is still not adequate among international and Saudi pilgrims,
despite the vaccine policies in place.31 An average of 39 400
vaccinations were administered annually between 2000 and 2006
in Bahrain, primarily at public health centers.32 In 2001 only 2.6%
of the UAE population was reported to have been vaccinated.21
Implementation of the school-based polysaccharide MenAC
vaccination program in Egypt appears to have interrupted the cycle
of outbreaks, which had been occurring with a periodicity of 8
years (1967–91). Following the introduction of the vaccine, the
incidence rates of endemic meningococcal disease decreased from
0.7–2.0 per 100 000 in 1967–95 to 0.1 per 100 000 in 2006.26
Implementation of vaccination with the quadrivalent vaccine in
the Israel Defense Forces was associated with a decrease in the
incidence rate of vaccine-preventable meningococcal disease from
1.31 cases per 100 000 person-years in 1983–94, to 0 in 1995–
2007, the period following implementation of the vaccine.33
5. Meningococcal disease outbreaks in MENA
Meningococcal outbreaks generally follow a cyclical pattern
with a seasonal distribution. Several countries in MENA have
experienced multiple outbreaks over recent decades (Table 18–
10,14–17,21,22,24,26,28–30,32,34–83). Egypt experienced meningococcal
disease outbreaks every 8 years (1973–74, 1982–84, and 1988–
91), but has not had an outbreak reported since the school-based
vaccination policy was implemented.26,84 The outbreaks in Egypt
lagged behind outbreaks in Sudan by 1 to 2 years, suggesting a
northerly spread of increased disease prevalence. Outbreaks have
occurred most frequently in Sudan, which is highly susceptible to
meningococcal outbreaks as it is a part of the African meningitis
belt. Following an outbreak involving more than 33 000 people in
1999,8,34 subsequent outbreaks of more than 1000 cases occurred
in Sudan in 2000 (4031 cases),8 2003 (1113 cases),28 2006 (5000
cases),35 and 2007 (6946 cases).9,10
Epidemic clones have historically spread across continents, as
demonstrated by the serogroup A-associated outbreaks that
initially spread from Nepal in 1983 to New Delhi, then spreading
further to the Hajj in Saudi Arabia in 1987.36 Serogroup A-
associated outbreaks were then observed in MENA starting in
Qatar,37 spreading to Pakistan and Sudan by 1988,36 and Morocco
by 1989.8 Serogroup W-135 Hajj-associated outbreaks have also
spread across MENA, and subsequently spread to other countries
worldwide during 2000–01.85 Small serogroup B and C outbreaks
have occurred in Israel.38–42
Pilgrims of the Hajj and Umra pilgrimages have been
particularly affected by meningococcal disease outbreaks, in some
cases resulting in further dissemination of disease in the pilgrims’
home countries. Overcrowded conditions associated with the
pilgrimages can facilitate the rapid ampliﬁcation and dissemina-
tion of disease among pilgrims and Saudi nationals.85 Since the
pilgrimage often coincides with the meningitis season in the
African meningitis belt, there is the potential for further disease
Table 1
Neisseria meningitidis serogroups identiﬁed, outbreaks, and disease incidence in countries of MENA
Country Meningococcal serogroups Outbreaks Incidence
Serogroups detected in
serogrouping studies
Year Identiﬁed
serogroups
Number of
cases
Number of years with
data available between
1986 and 2011
Most recent incident
rate available,
per 100 000
Afghanistan14 No data 4 0.4 (1989)
Algeria70–72 No data 1997 W-135 7 0.7 (2005)
1999 W-135
Bahrain14,32 No data 20 0 (2009)
Egypt14,24,26,46–49 A, B, C, D, W-135, Y, Z 1973–1974 Shift from
A to B over time
13 0.1 (2006)
1982–1984
1988–1991
Iran14,46,69 B, C 12 0.14 (2005)
Iraq14,46 No data 11 0.18 (2005)
Israel38–42,57,59–62 A, B, C, W-135, Y 1998–1999 B 9 1.22 (1998)
1996–1999 C
1992–1995 B
1992–1993 C
1991–1996 B
1991–1994 C
Jordan14,56 No data 21 0.30 (2006)
Kuwait14,64,65 A, B, C, W-135, X, Y, Z 24 0.23 (2009)
Lebanon14 No data 1 0.15 (1993)
Libya14,46 No data 9 2.01 (2005)
Morocco8,30,46,53,54 A, B, C, W-135, Y 1989–1990 A 1915 19 5.24 (2005)
Oman8,14,24,29,43,73 A, C, W-135 2001 Majority W-135 14 22 0.10 (2007)
2000 Majority W-135 22
Pakistan14,74 No data 1988 A 112 8 5.41 (1995)
Palestine14,58 No data 12 2.62 (2005)
Qatar14,37,46,63,65 A, B, W-135, Y 1987 A 112 14 0.73 (2006)
Saudi Arabia8,14–17,29,36,44,67,68,72,75–77 A, B, C, W-135 2001 Majority W-135,
minority A
274 19 0.09 (2006)
2000 W-135 and A 304
1998 Majority A 20
1997 A 72
1992 A 102
1987 1841
Sudan8–10,14,28,34–36,45,46,78–83 W135 2007 571 16 13.26 (2006)
2007 A detected 6946
2006 A and W135 5000
2006 A detected 231
2005 No data 3673
2005 Majority W135 71
2005 A detected 250
2003 1113
2000 Majority W135 4031
2000 NR 1437
1999 A 33 313
1998–99 NR 4000
1988 A 18 000
Syria14,46 No data 11 0.07 (2005)
Tunisia14,46,50–52 A, B, C 11 2.86 (2005)
Turkey22,55 A, B, W-135, Y 1 0.88 (2004)
UAE14,21,65 No data 10 1.0 (2008)
Yemen14,66 No data 9 4.74 (2005)
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serogroup A outbreak in Saudi Arabia, the majority of the 1841
cases were reported in Mecca, Medina, and Jeddah, the cities
closely associated with the pilgrimage.15 In 2000 and 2001 an
outbreak occurred primarily due to serogroup W-135, with
serogroup A also detected.16,29 More than 50% of the 1300 cases
in 2000 and 1109 cases in 2001 were conﬁrmed to be due to
serogroup W-135, making this the ﬁrst large serogroup W-135
outbreak identiﬁed worldwide.86 A retrospective study that
included 729 conﬁrmed meningococcal meningitis cases from
1999 to 2002, found that 42% of cases were in pilgrims and 58% in
the local population. Fifty-eight percent of cases were in children
less than 5 years of age.17 In 2002 there was a major serogroup W-
135 epidemic, which affected several countries in the African
meningitis belt as a result of the spread of the Hajj outbreak clone
from pilgrims to close contacts.87 The spread outside of MENAillustrates how meningococcal disease epidemiology in one region
can impact other parts of the globe.
High case fatality rates (CFR) have been reported in association
with meningococcal disease outbreaks, particularly serogroup W-
135 outbreaks. CFRs during the 2000 W-135 outbreak were
reported to be 26–28% in Saudi Arabia,16,29 11–21% in Oman,43,88
and 60% among patients admitted to a Mecca hospital.44 In
comparison, the CFR for the 2000 serogroup W-135 outbreak in
Sudan was reported to be 8%,8 which may be due to under-
reporting, given the lack of health care infrastructure reported in
Sudan.45
Meningococcal disease caused by the serogroup W-135
outbreak strain associated with the Hajj were reported in Iran,
Kuwait, Morocco, Oman, Singapore, the USA, Senegal, Mauritius,
and nine European countries.29,88 In Europe, most cases appeared 2
weeks after the ﬁrst pilgrims returned. Of all cases reported in
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pilgrim contact, and 24% were unknown. The average CFR for these
European cases was 16%.89
6. Meningococcal carriage in MENA
Cases of meningococcal disease are the most noticeable public
health outcome, however carriage of N. meningitidis is common,
and most transmission occurs through asymptomatic carriage.90
Age-stratiﬁed carriage data can be used to describe the natural
state of N. meningitidis; these data are necessary to understand key
age groups contributing to transmission and can be used to identify
serogroups that are present and circulating in the population. Such
data are necessary for the development of mathematical models to
explore the longer term impact of vaccination on disease in the
region. Unfortunately, very limited published data are available for
N. meningitidis carriage in MENA, and existing data are becoming
historical. As data are only available for nine of the 23 MENA
countries, it is difﬁcult to make comparisons between countries or
to examine trends over time. Very few studies reﬂect the general
population across the whole age range.91–94 A study of the general
population in Egypt conducted in 1992–93 found a carriage
prevalence of 4%.91 Carriage in the general population in Israel was
6.6% in a study undertaken from 1987 to 1990.92 Carriage
prevalence among the general population in three cities in Saudi
Arabia in 2002 were reported to be 1.1% or lower.93,94 The majority
of carriage studies were undertaken in perceived risk groups,
targeted certain age groups, or were undertaken in response to an
outbreak. Pediatric data (among children up to 14 years of age)
from Egypt95 and Turkey96,97 show a wider range of carriage (1.2–
18.8%). Higher carriage prevalence has also been observed in
military personnel (up to 38.3%)98 and students (up to 24%).99
However, in a 2003 study of Hajj pilgrims, N. meningitidis carriage
was only detected in 11 of 344, suggesting a lower than expected
colonization rate.100 In a study of Iranian Hajj pilgrims, carriage
prevalence of N. meningitidis was 5.3% before and 4.6% after
pilgrimage.101 Very limited data are available estimating age-
speciﬁc carriage prevalence. Two Israeli studies reported that the
highest carriage prevalence was observed in 11–15-year-olds
(29%)92 and 1–9-year-olds (15.3%),41 while a Mecca and Medina
study reported highest carriage in children less than 5 years of age
(8.3%).94
Carriage studies that investigate the serogroup distribution are
also limited. Countries with relevant published data include
Egypt,91,98,102,103 Iran,101 and Israel.41,92 Serogroups A, B, and C
were most commonly identiﬁed as being carried, with studies in
Israel92,104 and Iran101 also reporting some carriage of serogroup Y.
However, these studies often targeted populations considered to be
at higher risk of carriage or disease, with much of the published data
from studies undertaken in the 1990s and now becoming historical.
Systemic antibiotics given within 48 h of diagnosis of a case can
clear nasopharyngeal carriage and prevent secondary cases, however
this is only recommended by the WHO in special circumstances, and
mass chemoprophylaxis to prevent or control outbreaks is not
recommended.14 Reports of chemoprophylaxis for carriers in
Egypt,101 Israel,92 and Iran101 have demonstrated a temporary
reduction in carriage. Whilst carriage is a pre-requisite for disease,
and an increasing carrier prevalence could increase the risk of illness
occurring in non-immune persons, the relationship between carriage
and the incidence of disease remains poorly understood.14
Several studies from MENA have contributed evidence to
illustrate that polysaccharide meningococcal vaccines do not
prevent acquisition of meningococcal carriage. No difference in
carriage was detected between vaccinated and non-vaccinated
Mecca and Medina residents,94 and two carriage studies with
pilgrims from Singapore and the USA reported that all pilgrimswho became carriers had previously been vaccinated with
polysaccharide vaccine.105,106 A carriage study with military
recruits in Egypt determined that polysaccharide MenAC vaccina-
tion had no impact on the overall carriage prevalence.102 In
contrast, there is compelling evidence that MenC conjugate
vaccines reduced carriage following their introduction into routine
programs in Western Europe, impacting transmission and enabling
some herd protection to be generated.107 Presently, two tetrava-
lent meningococcal conjugate vaccines against serogroups A, C, W-
135, and Y – Menactra1 and Menveo1 – are available, with
Menactra already licensed in the Gulf Cooperation States (Bahrain,
Kuwait, Oman, Qatar, Saudi Arabia, and the UAE). These conjugate
vaccines may offer new opportunities for disease control in the
region. In order to determine the impact these conjugate vaccines
could have, and to better understand transmission dynamics, more
comprehensive carriage data in MENA are required, particularly
studies across the age range and reﬂecting the general population.
Countries considering wider or routine use of conjugate vaccines
may ﬁnd generating carriage data is valuable in order to explore
both direct and indirect beneﬁts of vaccine use, and to facilitate
mathematical modeling to help guide vaccine policies and
evaluation of vaccine impact.
7. Regional meningococcal disease epidemiology in MENA
Available data on meningococcal disease incidence in MENA are
disparate in nature, and regularly published data in the literature
or as part of routine surveillance are generally lacking (Table 1).
Data on incidence during outbreak periods appear to be more
readily available, but the focus on data collection during outbreaks
may bias the ability to determine the underlying incidence of
disease in the region.
7.1. Northern Africa (Morocco, Tunisia, Algeria, Libya, Egypt)
Very limited meningococcal incidence data are available for
Algeria. For Libya, data were available for 1986–93, then again for
2005, at which time the incidence was 2.01 per 100 000.46 Reported
incidence in Egypt was more variable due to the cyclical outbreaks,
reaching a peak of 7.22 per 100 000 in 1989.14 Over the last 15 years
much lower rates have been reported, closer to 0.1 per 100 000, and
some evidence of a shift was seen in those serogroups causing
disease. Between 1966 and 1992 (pre-MenAC vaccination period),
approximately 95% of meningococcal cases in Egypt were serogroup
A and approximately 4% were serogroup B;26,47however, since 1997,
26–59% of cases observed have been attributed to serogroup A and
5–66% to serogroup B.24,26,48,49 Additional data are needed to better
understand these ﬂuctuations and any associated factors that may
have contributed. In Tunisia the highest incidence rate was reported
in 1987,25 but the only available incidence after 1996 was much
lower, at 2.86 per 100 000 in 2005.46 In addition to the presence of
serogroups A and C, serogroup B was reported as the primary
serogroup in two studies in Tunisia,50,51 and a neonatal case of
serogroup B was also reported recently.52 Reported incidence rates
for Morocco have remained below 2 per 100 000 since 1992,46,53
with the exception of 2005, when the rate reached 5.24 per
100 000.46 Serogroups A and B are most frequently responsible for
disease in Morocco, with serogroups C, W-135, and Y also
reported.30,53,54 Serogroup B has been reported to be responsible
in up to 57% of cases using data from the past decade.53
7.2. Eastern Mediterranean (Turkey, Syria, Lebanon, Israel, Jordan,
Palestine)
Incidence rates were only reported twice for Turkey and once
for Lebanon between 1986 and 2011. In Lebanon the rate was 0.15
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in 200455 and 3.5 per 100 000 in 2006.22 Data for Syria show
incidence rates less than 5 per 100 000 through 1995,25 but
subsequently the only rate reported was in 2005, when the rate
had decreased to 0.07 per 100 000.29 In Jordan, where incidence
data were available yearly from 1986 to 2006, rates have been
consistently low, and have not exceeded 1 per 100 000 since
1995.25,56 Reported incidences from Israel between 1995 and 1998
were also low, ranging from 1 to 1.75 per 100 000.25,57 In Palestine,
reported incidence rates from 1986 to 1993 were less than 0.6 per
100 000,25 with the highest reported rate in 2003, at 4.3 per
100 000.58 Serogroup data were available for Israel, where
serogroups B and C were most frequently responsible for disease,
in addition to the less frequently detected serogroups A, W-135,
and Y.38,39,41,57,59–62 In Turkey in 2005–06, serogroups W-135 and
B were most commonly reported, with serogroups A and Y also
observed.22 No serogrouping data were found for the other
countries in this region.
7.3. Saudi Arabian Peninsula and Gulf States (Saudi Arabia, Bahrain,
Yemen, Oman, Qatar, the UAE, Kuwait)
In Bahrain, Oman, and Qatar, all reported incidence rates
were below 2 per 100 000, with the exception of a few higher
rates in the mid 1980s.25,32,46,63 In Kuwait the incidence rate
declined to 0.23 per 100 000 in 2009.27,64 The most recently
reported incidence rate for the UAE was 1.0 per 100 000 in
2008,65 while prior to 1993 rates ranged from 1.82 per 100 000
in 1992 to 16.53 per 100 000 in 1987.25 Rates in Yemen have
been sporadically reported and have varied substantially from
72.42 per 100 000 in 198825 to less than 5 per 100 000 from
2003 to 2005.66 In 1987 the incidence rate in Saudi Arabia was
12.83 per 100 000,25 but following that peak has remained low,
with the highest rate reported in 2000, of 1.65 per 100 000,67
with only six cases reported in 2009.65 Serogroups A, B, C, and
W-135 have been documented as causing disease in Saudi
Arabia, where serogroups A and W-135 are the most commonly
reported.8,16,17,29,44,69,75 The majority of cases in Kuwait were
caused by serogroups B and W-135.27,64 Between 2001 and
2008, serogroups A, B, C, W-135, and Y were all documented in
cases of disease in Oman, with serogroups A and W-135 the
most commonly reported.65 No serogrouping data were found
for the other countries in this region.
7.4. Eastern Region (Iran, Iraq, Pakistan, Afghanistan)
The only reported incidence rates since 1996 for both Iran and
Iraq were for 2005, when the rates were 0.14 and 0.18 per 100 000,
respectively.29 In the decade preceding 1996, incidence rates for
Iraq varied considerably, ranging from 5.9 per 100 000 in 1987 to
30.37 per 100 000 in 1991. In Iran rates were consistently lower
and steadier, peaking at 1.38 per 100 000.25 The most recent rate
available for Pakistan was in 1995, when the rate was 5.41 per
100 000, with similar rates reported in the 10 years preceding
this.25 The only data from Afghanistan, from 1986 to 1989, peaked
at 0.4 per 100 000 in 1989.25 Serogrouping data were only available
for Iran, where serogroup B, and more commonly serogroup C,
were documented.69
8. Conclusions
This review describes the meningococcal disease outbreaks and
endemic meningococcal disease that particularly affects young
children across countries in MENA. It also underscores the key gaps
in our knowledge and the limited availability of contemporary
published data describing meningococcal disease epidemiology inMENA. Published estimates of meningococcal disease incidence
vary within MENA and are substantially higher in some countries,
indicating that meningococcal disease remains a public health
concern in some parts of the region. Overall, meningococcal
disease incidence appears to have steadily decreased across MENA
over the past 20 years. The highest disease incidence rates (12.9–
129.3 per 100 000) occurred during the 1987–89 outbreaks caused
by serogroup A in Sudan, Yemen, Tunisia, the UAE, Iraq, and Saudi
Arabia. Following that epidemic, the highest reported disease
incidence rates each year have ﬂuctuated from 1.44 per 100 000 in
199657 to 101.6 per 100 000 in 1999.34 Despite this, meningococcal
disease remains a cause of endemic disease in many MENA
countries, with low endemic rates (0.07–0.73/100 000) in most
countries, higher rates (2.01–5.24/100 000) in Libya, Morocco,
Palestine, Tunisia, and Yemen, and the highest rate (13.26/
100 000) observed in Sudan.
Meningococcal disease in this region appears to be predomi-
nant in children 5 years of age and younger, though outbreaks of
the disease often affect older age groups. Although serogroup A
remains the main cause of disease in MENA countries, cases of
serogroup B and W-135 have been increasingly reported during
1990–2006 in some areas, with serogroup Y also observed in
several countries.13,22,24,30,48,53,60
The Hajj pilgrimage constitutes a key factor inﬂuencing the
epidemiology of meningococcal disease both within MENA and
globally. Multiple outbreaks have affected the pilgrims them-
selves, as well as their close contacts in MENA and in more
distant home countries, and these outbreaks have helped shape
public health policy regarding meningococcal vaccination in the
region. In order to provide protection for the pilgrims, seasonal
workers, and citizens of Saudi Arabia who come into contact
with the pilgrims, vaccination policies have been and continue
to be updated, and may account for some of the changing
epidemiology and serogroup distribution in the region. The
combination of those serogroups observed as causing disease in
the region, in conjunction with the presence of additional
serogroups in countries surrounding the region, suggests the use
of a polyvalent conjugate vaccine could be valuable in
preventing disease spread, particularly in the context of the
Hajj. Vaccine policies for this region will help reduce the spread
of localized outbreaks affecting the Hajj pilgrims, also minimiz-
ing the effects on the home countries of the pilgrims and
decreasing global dissemination of disease. Additionally, in
certain home countries of pilgrims (the European Union (EU)
and the USA) serogroup B is an important cause of meningo-
coccal disease87 and has also been shown to be frequently
carried in carriage studies in the EU.108 There is also some
evidence that serogroup B may be carried within the MENA
region and is now additionally observed to be contributing to
disease in certain MENA countries. This suggests there is a
possibility for Hajj-related serogroup B disease outbreaks, which
should not be ignored, and once appropriate serogroup B
vaccines become available their potential role for protecting
pilgrims against possible outbreaks of serogroup B disease
should be considered.13
While a number of countries have some surveillance
capacity, few countries have systems that are up to the standard
recommended by the WHO.14 Surveillance systems in MENA
also need strengthening, with routine data needing to be
reviewed and published more regularly, in order to provide
reliable estimates of disease incidence, carriage, disease-related
mortality, and sequelae. No data appear available for several
countries, and only limited data were available for a number of
countries over the period reviewed. Sharing contemporary data
between countries in the region may also facilitate the
development of appropriate interventions and support public
M. Ceyhan et al. / International Journal of Infectious Diseases 16 (2012) e574–e582e580health decision-making regarding meningococcal disease. The
presentation of data collected through the ministries of health
or the established surveillance systems in an international
setting will also help to provide a more comprehensive
understanding of meningococcal disease in the region.
The expansion of current vaccination policies and consideration
of using available meningococcal vaccines will be important next
steps for MENA to decrease the burden of meningococcal disease
and to provide broader protection against the range of serogroups
that either contribute to disease or pose a threat. Countries
interested in either implementing routine conjugate vaccination or
updating existing policies already in place should also consider
introducing or strengthening existing regular surveillance for
meningococcal disease in order to assess the impact of vaccination
and to maximize its impact in the region.
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